Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Curis Inc CRIS

Healthcare Biotechnology
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK... see more

Recent & Breaking News (NDAQ:CRIS)

Curis Reports Third Quarter 2017 Financial Results

GlobeNewswire November 7, 2017

Curis, Inc. to Host Earnings Call

Accesswire November 7, 2017

Curis to Present at the Society for Immunotherapy of Cancer 32nd Annual Meeting and the Cowen IO NEXT Summit

GlobeNewswire November 3, 2017

Biotech Stocks on Investors' Radar -- Curis, Egalet, Esperion Therapeutics, and GlycoMimetics

PR Newswire November 2, 2017

Curis to Release Third Quarter 2017 Financial Results and Hold Conference Call on November 7, 2017

GlobeNewswire November 1, 2017

Developments in the Cancer Immunotherapy Market

PR Newswire October 20, 2017

Curis to Present at the Cantor Fitzgerald Global Healthcare Conference

GlobeNewswire September 22, 2017

Curis Announces Pricing of Public Offering of Common Stock

GlobeNewswire September 14, 2017

Curis Announces Proposed Public Offering of Common Stock

GlobeNewswire September 13, 2017

Stocks Under Scanner in the Biotech Space -- Curis, Egalet, and Esperion Therapeutics

PR Newswire September 13, 2017

Aurigene, a Wholly Owned Subsidiary of Dr. Reddy’s, and Curis Announce CA-170 Program Update Following Data Presented at ESMO 2017

Business Wire September 12, 2017

Curis and Aurigene Announce CA-170 Program Update Following Data Presented at ESMO 2017

GlobeNewswire September 11, 2017

Curis to Present at the Baird 2017 Global Healthcare Conference

GlobeNewswire September 6, 2017

Curis Announces CA-170 Poster Presentation at ESMO 2017 Congress

GlobeNewswire August 31, 2017

Curis Reports Second Quarter 2017 Financial Results

GlobeNewswire August 3, 2017

Investor Network: Curis, Inc. to Host Earnings Call

Accesswire August 3, 2017

Curis to Release Second Quarter 2017 Financial Results and Hold Conference Call on August 3, 2017

GlobeNewswire July 26, 2017

Technical Insights on Biotech Stocks -- Curis, OvaScience, Regulus Therapeutics, and Vanda Pharma

PR Newswire July 12, 2017

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire July 5, 2017

UPDATE - Curis to Present at the Jefferies Healthcare Conference

GlobeNewswire June 1, 2017